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and S. enterica serovar Typhimurium
targeting a novel synthetic lethal pair,
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Kathleen A. Andrews2, Bernhard Ø. Palsson2 and Pep Charusanti2,5*
1 Department of Microbiology and Immunology, Faculty of Pharmacy, Cairo University, Cairo, Egypt, 2 Department of
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Research, Inc., Albany, NY, USA, 4 Biology and Pharmacology, Albany Molecular Research Singapore Research Centre, Pte.
Ltd., Singapore, Singapore, 5 The Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark,
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Mathematical models of biochemical networks form a cornerstone of bacterial systems
biology. Inconsistencies between simulation output and experimental data point to gaps
in knowledge about the fundamental biology of the organism. One such inconsistency
centers on the gene aldA in Escherichia coli: it is essential in a computational model
of E. coli metabolism, but experimentally it is not. Here, we reconcile this disparity
by providing evidence that aldA and prpC form a synthetic lethal pair, as the double
knockout could only be created through complementation with a plasmid-borne copy
of aldA. Moreover, virtual and biological screening against the two proteins led to a
set of compounds that inhibited the growth of E. coli and Salmonella enterica serovar
Typhimurium synergistically at 100–200 μM individual concentrations. These results
highlight the power of metabolic models to drive basic biological discovery and their
potential use to discover new combination antibiotics.
Keywords: synthetic lethality, antibiotic development, drug discovery, systems biology, metabolic reconstruction,
bacterial metabolism, model-based drug target discovery, pathway gap filling
Introduction
Metabolic network reconstructions are systems biology tools that capture in one framework the
function of all known genes, proteins, and reactions within the metabolic network of an organism
(Palsson, 2011). The conversion of a metabolic reconstruction into a computational format allows
one to simulate ﬂux states of the network that correspond biologically to diﬀerent phenotypes,
and thereby to computationally investigate the genotype–phenotype relationship for an organism.
The ability to simulate diﬀerent phenotypes distinguishes computational models from static maps
of biochemical pathways. The latter provides a pictorial diagram of all pathways in a network
but no information on their usage or activity levels in a living organism, while the former
provides information regarding which pathways are actually active under the simulation condition.
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Diﬀerent sets of pathways will be active under diﬀerent
conditions, a situation referred to as the functional states of the
network.
One application of metabolic reconstructions and their
associated mathematical models is to drive new biological
discovery (Chen and Vitkup, 2006; Reed et al., 2006; Orth
and Palsson, 2012). The workﬂow consists of a loop in which
simulation output is ﬁrst compared to experimental data to ﬁnd
inconsistencies between the two. Hypotheses are then formed
to reconcile the two data types and subsequently tested in
the lab. New information gleaned from the experiments is
then incorporated into the model, after which a new cycle of
simulation, testing, and model reﬁnement begins. Each cycle
improves the accuracy, predictive ability, and therefore utility
of metabolic models. Metabolic models have already been used
to aid strain design for metabolic engineering (Lee et al., 2005;
Perez Pulido et al., 2005; Park et al., 2011; Licona-Cassani et al.,
2012), to analyze network properties (Almaas et al., 2005; Nam
et al., 2012), and to provide context for the analysis of high-
throughput omics data (Chandrasekaran and Price, 2010; Chang
et al., 2010; van Berlo et al., 2011), and their role in such projects
is anticipated to grow as the models are reﬁned and simulate a
larger number of biological conditions more accurately.
As another application, we recently used metabolic models
of four species of Enterobacteriaceae to guide the search for
synthetic lethal (SL) gene pairs in these bacteria (Aziz et al.,
Submitted). Metabolic models accelerate this search since they
can compute the impact of all double deletion mutants on
growth. Gene pairs that result in in silico synthetic lethality
become candidates for experimental validation. In this way,
metabolic models narrow a very large search space of all possible
double deletion mutants down to a more focused subset. For
Saccharomyces cerevisiae, the use of a metabolic model improved
the search for SL gene pairs by two orders of magnitude
over random selection of gene pairs (Harrison et al., 2007).
Validated SL pairs are signiﬁcant because they are potential drug
targets, for example as targets for antibiotic development against
pathogenic bacteria, since the inhibition of both enzymes leads
to cell death. Metabolic models consequently form a potential
bridge from basic biology to translational medicine by facilitating
the discovery of a speciﬁc class of combination therapeutics.
Drug combinations have garnered interest in antibacterial drug
discovery since recent studies suggest that the number of single
drug targets in bacteria is limited (Becker et al., 2006; Payne et al.,
2007).
In the current version of the Escherichia coli metabolic
reconstruction (Orth et al., 2011), there is an inconsistency that
centers on the gene aldA: it is essential for in silico growth
in glucose M9 medium, but the knockout mutant is viable
experimentally. Here, we present experimental data suggesting
that aldA is not singly essential because it forms an SL pair with
prpC. We also perform virtual and biological screening against
these two enzymes to search for sets of compounds that inhibit
growth of the bacteria, and ﬁnd one set that inhibits the growth of
E. coli and Salmonella enterica serovar Typhimurium (hereafter
referred to S. Typhimurium) synergistically at 100–200 μM
concentrations.
Materials and Methods
Bacterial Strains and Media
Escherichia coli wild-type, E. coli aldA, and E. coli prpC
were taken from the Keio collection (Baba et al., 2006)
and used for construction of the aldA prpC mutant
via complementation. An E. coli K12 MG1655 aldA was
used for transposon mutagenesis. A third strain of E. coli
was used for biological screening and is noted below. All
strains were grown in either Luria-Bertani (LB) broth/agar or
glucose M9 media. The M9 medium contained 2 g/L glucose,
100 μM CaCl2, 2 mM MgSO4, 6.8 g/L Na2HPO4, 3 g/L
KH2PO4, 0.5 g/L NaCl, 1 g/L NH4Cl, and 250 μL/L trace
elements. The trace element solution consisted of (per liter):
FeCl3·6H2O (16.67 g), ZnSO4·7H2O (0.18 g), CuCl2·2H2O
(0.12 g), MnSO4·H2O (0.12 g), CoCl2·6H2O (0.18 g), and
Na2EDTA·2H2O (22.25 g). Antibiotics were added as necessary
at the following concentrations: ampicillin at 100 μg/mL,
kanamycin at 50 μg/mL, and chloramphenicol at 25 μg/mL.
LB powder was purchased from EMD Chemicals (Gibbstown,
NJ, USA) and used at the manufacturer’s recommended
concentration. All other chemicals were purchased from Fisher
Scientiﬁc (Waltham,MA,USA) or Sigma-Aldrich (St. Louis,MO,
USA).
Growth Rate Determination
The Bioscreen C instrument (Oy Growth Curves Ab Ltd.,
Finland) was used to measure the optical density of the samples
for growth rate calculations. Brieﬂy, 400 μL samples of each
strain were pipetted into separate wells in triplicate. The initial
OD600 was 0.05. The plate was then placed into the instrument,
and OD600 measurements taken every 15 min over 48 h.
The plate was shaken for 10 s prior to each reading, and the
incubation temperature was 37◦C. The growth rate was calculated
in Microsoft Excel as the slope of the straight line that was best
ﬁt to the logarithm of the OD600 values during the exponential
growth phase.
Metabolic Modeling and Prediction of Single
Gene Essentiality
Metabolic network reconstructions for E. coliK12MG1655 (Orth
et al., 2011) were loaded into the COBRAToolbox (Ebrahim et al.,
2013). Default bounds were retained for all model reactions (Orth
et al., 2011). To simulate glucose M9 and LB media conditions,
we adjusted the lower bound of each exchange reaction according
to the media composition (Aziz et al., Submitted). For example,
lower bounds for M9minimal media were set at−1000 (allowing
unlimited uptake) on the exchange reactions for Ca2+, Cl−,
CO2, Co2+, Cu2+, Fe2+, Fe3+, H+, H2O, K+, Mg2+, Mn2+,
MoO42−, Na+, Ni2+, SeO42−, SeO32−, and Zn2+ as previously
detailed (Monk et al., 2013). Single knockout mutants were
modeled by using the delete_model_gene function to constrain
each reaction catalyzed by the corresponding enzyme to zero.
Model growth phenotypes were determined using ﬂux balance
analysis (FBA) with the core biomass reaction as the objective.
If a particular knockout resulted in a simulated growth rate equal
to zero, that gene was deemed to be singly essential. The Gurobi
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(Gurobi Optimizer Version 5.6, Gurobi Optimization, Inc.) linear
programming solver was used to perform FBA.
Transposon Mutagenesis
To create the aldA transposon library, we grew a freshly
inoculated colony of the aldA knockout strain to an optical
density of 0.8 in LB at 37◦C, then harvested the cells and made
them competent by washing three times in chilled 10% glycerol.
Fifty microliters of the washed cell pellet was transformed with
1 μL of EZ-Tn5 transposome (Epicenter, Illumina, USA) by
electroporation (BioRad electroporator at 2500 V), and the
electroporated cells were recovered by incubation in SOC media
to a ﬁnal volume of 1 mL. An aliquot of the library was tested for
the presence of transposon and for purity. Tn5-transformed cells
were selected as single colonies on LB agar containing 50 μg/mL
kanamycin; no heterogeneous colonies were observed.
The genetic loci that were disrupted by the EZ-Tn5 transposon
were identiﬁed by the rapid ampliﬁcation of transposon ends
(RATEs) method (Ribot et al., 1998). Brieﬂy, DNA from selected
colonies was ampliﬁed by a three-stage PCR: the ﬁrst stage is a
unidirectional primer extension reaction using inverse primers
that linearly amplify segments of random lengths corresponding
to the inserted transposon ends. The second stage is a permissive
PCR that uses the same primers non-speciﬁcally to generate
random double stranded fragments of the two transposon ends
extended in the ﬁrst stage. The third stage is now a highly
speciﬁc PCR that ampliﬁes the random-length double-stranded
fragments, which include portions of the two insertion sites,
which are of enough length to determine the identity of those
insertion sites by Sanger sequencing.
Construction of Knockout Mutants
All gene knockouts were created using the protocol of Datsenko
and Wanner (2000). Brieﬂy, a kanamycin resistance cassette
containing ﬂanking FRT sites was generated by PCRusing pKD13
as the template. The ends of the cassette comprised 60 nucleotides
that contained the start or stop codon plus 57 bp that were
homologous to the 57 bp immediately upstream and downstream
of gene to be deleted. PCR and Sanger sequencing conﬁrmed
correct insertion of the marker and subsequent removal from the
chromosome. All PCR products were puriﬁed with the QIAGEN
PCR clean-up kit (Valencia, CA, USA).
aldA Complementation
The pASK1988 plasmid (Fong et al., 2013), based on pASK-
iBA33+ (IBA GmbH, Goettingen, Germany), was used for
complementation. The aldA gene was inserted into pASK1988
by PCR amplifying the backbone of the plasmid and the aldA
gene such that the two fragments had 21 or 22 bp overlapping
sequences on each end of the two fragments. The two fragments
were then mixed together, and PCR cycling used to anneal them
together. The plasmid was gel puriﬁed, and correct insertion
of aldA veriﬁed by Sanger sequencing. This plasmid was next
transformed into the E. coli prpC via electroporation.
To construct the prpC aldA mutant, we inoculated
1 mL of an overnight culture of E. coli prpC bearing
the complementation plasmid into each of four Erlenmeyer
ﬂasks containing 100 mL LB plus chloramphenicol. Expression
of the target gene on this plasmid is normally induced by
anhydrotetracycline (aTc). As such, aTc was added at 0, 50, 100,
and 200 μg/mL concentrations to the four cultures, and all four
were incubated at 30◦C for 3–4 h. The four cultures were then
washed three times with ice-cold 10% glycerol, after which they
were transformed with the aldA knockout cassette. Colonies
bearing deletions in both prpC and aldA were conﬁrmed by PCR
and Sanger sequencing. Interestingly, the culture in which no
aTc had been added was the only one that yielded colonies after
transformation, suggesting constitutive rather than inducible
expression. The selection marker for the knockout cassette
(kanamycin resistance) was then cured from the prpC aldA
mutant using pCP20 following standard protocol (Datsenko
and Wanner, 2000). The mutant also regained sensitivity to
chloramphenicol, the selection marker for pASK1988; however,
a plasmid-borne copy of aldA could still be detected by
PCR using primers that ampliﬁed a region wholly within the
chloramphenicol resistance gene.
Protein Structural Modeling
The only available crystallographic structures for PrpC
come from organisms other than E. coli (e.g., Salmonella
Typhimurium). Therefore, a homology model for PrpC was
taken from a previously constructed template-based homology
model (PRPC_ECOLI) using the I-TASSER suite of programs
(Xu and Zhang, 2012, 2013). The structural assessment for AldA
is based on a native PDB template, 2hg2 (chain A; Di Costanzo
et al., 2007).
Virtual Screening and Compound Selection
Crystal structures of six proteins were selected from the protein
databank (www.rcsb.org), which were identical in sequence to
the proteins found in the two bacteria, and in total, 13 sites were
used for docking. Preference was given to those structures that
contained a co-crystalized substrate or inhibitor so that we could
select compounds that likely bind at a catalytic site. Standardized
methods were used to prepare each binding site for docking, and
to model the sites with compounds that confer appropriate shape
and electrostatic interactions for potential inhibitory compounds.
Diverse compounds from a library of 300,000 to 600,000
commercial compounds were docked using high throughput
virtual screening (HTVS) precision. The best scoring compounds
were subjected to atom pair similarity calculations (Carhart et al.,
1985) to determine chemically similar structures with a similarity
cutoﬀ of 70–80%. In addition, compounds that contained the
maximumHierS scaﬀolds (Wilkens et al., 2005) of any compound
on the HTVS list were also selected. The resulting combined
list of compounds was docked again using standard precision.
Compounds that docked well-according to the Glide docking
program and scored well-based on a complementary scoring
scheme were examined manually and purchased, if available.
Our selection choices were guided by the need for at least
one or two single-agent inhibitors per protein target. Therefore,
we set a goal of testing a minimum of 200 compounds per
protein target based on reported success rates of selecting true
active compounds in typical in vitro biochemical screens by
Frontiers in Microbiology | www.frontiersin.org 3 September 2015 | Volume 6 | Article 958
Aziz et al. aldA prpC synthetic lethality
docking methods. Docking methods provide a mean enrichment
factor of 1–60 over random selections with an enrichment of
10 being a reasonable expectation, or approximately a 10% hit-
rate (McGaughey et al., 2007). We also assumed that only ∼10%
of compounds would permeate the Gram-negative cell walls
yielding a net 1% hit rate in bacterial assays.
After identifying weak hits in the bacterial growth inhibition
assay, we selected chemically similar compounds and likewise
docked them to their putative binding site. The selection of
similar compounds was done using atom pair similarity (Carhart
et al., 1985) calculations with a similarity cutoﬀ of 70–80%. These
similar compounds were then docked using the same methods
as the original compounds. Any resulting compounds that met
the same docking score criteria as the original compounds were
purchased, if available.
Primary Compound Screening
The IC50 and percentage inhibition of each purchased compound
was tested in bacterial growth inhibition assay. E. coli (ATCC
25922) and S. enterica (ATCC 14028), both purchased from
American Type Culture Collection (Manassas, VA, USA),
were used for the growth inhibition assays. The strains
were propagated on BBLTM Mueller-Hinton II broth (Cation-
Adjusted) and BBLTMMueller-Hinton II agar (Becton, Dickinson
and Company, USA). The glycerol stocks were made and stored
at −80◦C. Colony-forming units (CFUs) were determined for
stocks and the assay inoculum to assess initial viability and
to ensure consistent assay performance. The bacterial growth
inhibition was measured using broth microdilution method.
All test compounds were dissolved in DMSO (20 mM) and
plated onto 384-well microtitre source plates (Corning, NY, USA)
using Biomek FX (Beckman Coulter, USA) in a twofold eight-
point dose response series (20 –0.156 mM). The assay plates
were stamped from source plates using Cartesian Hummingbird
(Digilab, Inc., USA) and each well received 500 nl of the
compound. Standard bacterial inoculum of 5 × 105 CFU/mL
was used for the assay and 50 μl per well was dispensed
using Multidrop (Thermo Fisher Scientiﬁc, Inc., USA). The
assay plates were incubated at 37◦C for 18 h and bacterial
growth was measured by absorbance at 600 nm. The IC50
of the test compounds were calculated using IDBS XLﬁt data
analysis software. To rule out any assay interference from the
test compounds, turbidity assessment for all the compounds
in Mueller-Hinton II broth was conducted at 600 nm. None
of the compounds exhibited signiﬁcant absorbance at 600 nm.
The assay performance was monitored for each assay plate
and Z’ scores of ≥0.5 and coeﬃcient of variation (CV) of
≤10% for positive and negative growth controls included in
each assay plate were kept as assay acceptance criteria. In
addition, reference antibiotics including amikacin, azithromycin,
ceftriaxone, chloramphenicol, levoﬂoxacin, and tetracycline
(Sigma-Aldrich, USA) were tested on the growth inhibition
assay as controls on each assay day. The minimum inhibitory
concentrations (MICs) were determined for these reference
antibiotics using standard Clinical and Laboratory Standards
Institute (CLSI) method. The assay plates were failed and retested
if they did not meet the assay acceptance criteria or if the shift
in the obtained MIC values of the reference antibiotics for any
strain/antibiotic combination exceeded >2-fold.
Combination Studies
A preliminary combination study was performed using four
compounds (ALDA-112, ALD-087, ALDA-70, and PRPC-034)
selected from the primary screening. Each compound was
tested in combination at two by two concentrations. Two
concentrations of each compound that caused 25 and 50% growth
inhibition of E. coli and/or S. Typhimurium were chosen for
the combination study. Based on the results of the primary
combination studies, three compounds were further shortlisted
for combination studies using eight by eight test concentrations
(top test concentration of 200 μM). The bacterial growth
inhibition assay was performed by methods as described in
the previous section. All the experiments were performed in
duplicates.
Results
In Contrast to Simulation Data, an E. coli
aldA Mutant is Viable
Simulations using the most recent version of the E. colimetabolic
model (Orth et al., 2011) suggest that aldA should be an essential
gene in glucose M9 media; however, the aldA mutant is
viable experimentally in this medium (Supplementary Figure
S1). Glycolaldehyde dehydrogenase A (AldA), encoded by aldA,
is an enzyme of broad speciﬁcity for small α-hydroxyaldehyde
substrates (Baldoma and Aguilar, 1987). It is known to oxidize
L-lactaldehyde to L-lactate in the metabolic pathways for L-
fucose and L-rhamnose utilization, and catalyzes glycolaldehyde
dehydrogenation of diﬀerent pentoses such as D-arabinose
and L-lyxose (LeBlanc and Mortlock, 1971; Badia et al.,
1991). This latter function (and its encoding gene aldA) is
predicted by the model to be essential for growth in glucose
M9 because of its role in the folate biosynthesis pathway.
In order for the model to synthesize folate, an essential
metabolite, dihydroneopterin aldolase (FolB) must convert
dihydroneopterin to 6-hydroxymethyl dihydropterin, which
produces glycolaldehyde as a by-product. AldA then converts
glycolaldehyde to glycolate (Figure 1). Without this reaction,
an inﬁnite amount of glycolaldehyde would accumulate in the
model, which is an infeasible solution because it violates mass
balance. Biologically, aldehydes are electrophilic compounds that
are often toxic. Therefore accumulation of glycolaldehyde during
the synthesis of folate due to an aldA gene disruption could be
lethal to growth of E. coli. The E. coli aldA mutant is viable
in glucose M9, however, suggesting that either glycolaldehyde
diﬀuses out through the membrane or is converted to glycolate
by a diﬀerent enzyme.
aldA and prpC Appear to be Synthetically
Lethal
Based on the inconsistency between simulation and experimental
data, we hypothesized that an unidentiﬁed enzyme could catalyze
the same essential reaction currently assigned only to AldA. To
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FIGURE 1 | The model-predicted essential pathway catalyzed by AldA. Glycolaldehyde is a by-product of the essential tetrahydrofolate synthesis pathway in
Escherichia coli. It is produced by dihydroneopterin aldolase, encoded by the gene folB. The aldA gene encodes glycolaldehyde dehydrogenase, which oxidizes
glycolaldehyde to glycolate. In an aldA knockout strain, the E. coli metabolic model predicts that glycolaldehyde will accumulate in the cell, leading to cell death
(Orth et al., 2011). Experimentally, however, aldA mutants are viable.
test this hypothesis, we used transposonmutagenesis to introduce
random gene disruptions in the aldA background and screened
for the absence of non-essential genes in the transposon library.
To verify these data, we subsequently attempted to create 15
double deletion mutants, each comprising aldA and one of
the top 15 hits from the screen. We could successfully create
fourteen of these double mutants and grow them in glucose M9
(Supplementary Table S1). Despite repeated attempts, however,
we failed to isolate a aldAprpC double mutant, even in LB
medium.
Based on this outcome, we hypothesized that aldA and prpC
might form a SL gene pair in both LB and glucose M9. To further
investigate this possibility, we cloned aldA into the pASK1988
overexpression vector (Fong et al., 2013), transformed it into a
prpC mutant, and re-attempted to create the double knockout.
With this complementation, we could successfully delete the
chromosomal copy of aldA. We next removed the kanamycin
selection marker and attempted to cure the overexpression
plasmid from the double mutant. All colonies regained sensitivity
to the selection marker present on the complementation plasmid
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(chloramphenicol resistance), but the presence of aldA could
still be detected within the double mutant (Figure 2 and
Supplementary Figure S2). These data support the hypothesis that
aldA and prpC are synthetically lethal.
Structural Comparison between AldA and PrpC
We compared the protein structures for AldA and PrpC to
investigate whether PrpC might have unrecognized promiscuous
dehydrogenase activity. AldA is comprised of 61.3% alpha
helix/beta sheet content versus 58.8% for PrpC, and the two
diﬀer in length by 90 amino acids (479 versus 389 for AldA
and PrpC, respectively, Figure 3). A pairwise comparison using
DALI (Holm and Rosenstrom, 2010), however, indicates very
little sequence and secondary structural similarity. Only 47 of the
479 (10%) residues in AldA have structural similarity to residues
in PrpC, and PrpC lacks any indication of an NADH binding
site (Figure 3). The likelihood that PrpC exhibits promiscuous
dehydrogenase activity is therefore low.
Virtual and Initial Biological Screening of
Drug-Like Molecules against AldA and PrpC
Identified Three Compounds with Potential to
Elicit Combination Effects
The protein products of validated SL pairs are potential drug
targets, and small molecule inhibitors against them are expected
to inhibit growth synergistically when the two compounds are
present in combination but have little to no inhibitory eﬀect when
they are present individually. Synergy is an attractive feature in
drug combinations (Lehar et al., 2009). We therefore evaluated
FIGURE 2 | Confirmation of the prpC aldA deletions at their
annotated chromosomal positions, and the continued presence of a
copy of aldA at an undefined location. Colonies were isolated in which the
chromosomal copies of prpC and aldA had been successfully deleted (lanes 3
and 5 versus lanes 2 and 4, respectively), but PCR amplification using primers
that targeted a region wholly within aldA revealed that a copy of this gene was
still present in the double mutant (lane 6). The identity of this amplicon was
also confirmed by Sanger sequencing. Abbrevations: WT, wild-type; DKO,
prpC aldA double knockout; ext, external; int, internal. Numbers on the far
left indicate DNA band sizes in kb.
the feasibility of ﬁnding synergistic inhibitors based on synthetic
lethality by performing virtual and biological screening against
AldA and PrpC. Compounds were initially screened to identify
those that inhibit bacterial growth weakly as single agents, after
which they were tested in combination with each other to
assess potential synergy, additivity, and antagonism among the
molecules.
Two hundred seventy-three compounds were identiﬁed
from virtual screening against AldA and PrpC. The selected
compounds were tested in an eight-point dose response format
(top test concentration of 200 μM and twofold dilution) against
E. coli and S. Typhimurium to determine their IC50 and percent
inhibition (where IC50 could not be established) against the
two bacteria. Although the virtual screening was carried out
against protein targets, biological screening was performed as
a growth inhibition assay in which the readout was bacterial
growth. For all bacterial growth assay plates, the Z’ scores were
greater than 0.5, and the percent CV for positive and negative
controls on each assay plate were less than 10%. Furthermore, the
MIC data generated with the reference antibiotics for each strain
were consistent between multiple experimental days, conﬁrming
uniformity across the screening campaign. Two compounds
targeting AldA, ALDA-112 and ALDA-170 exhibited growth
FIGURE 3 | Comparative structural analysis of (A) PrpC and (B) AldA. In
the left panel of (A), the region with the highest overlapping structural similarity
between PrpC and AldA is shown in green. The putative binding site with
catalytic residues H274 and D325 are shown in blue. In the native reaction,
2-methyl citrate synthase, oxaloacetate reacts with a CoA-ester (e.g.,
propionyl-CoA) to form (2R,3S)-2-hydroxybutane-1,2,3-tricarboxylate. The
NADH binding site is 15 Å away from the closest residue in the green
overlapping region, and is therefore not considered a part of the overlap.
Shown in the right panel of (A) is a magnification of the putative binding site.
In the left panel of (B), the region with the highest overlapping structural
similarity is again shown in green. The putative binding site (violet) shows
where lactic acid binds to the protein. The putative binding orientation of lactic
acid is taken from an alignment with PDB entry 3o8j.
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inhibition against E. coli with an IC50 of 108 and 200 μM,
respectively (Table 1). Two additional compounds, one targeting
AldA (ALDA-087) and one targeting PrpC (PRPC-034), showed
weaker activity against both E. coli and S. Typhimurium (>20%
inhibition at 200 μM). IC50 values could not be determined for
these two compounds due to their weak activity. The structures
are shown in Figure 4 and Supplementary Figure S3.
These four compounds were selected for combination
studies against both E. coli and S. Typhimurium. Initially,
two concentrations of one compound were tested against two
concentrations of another compound to produce a 2x2 matrix
for each of the six possible combinations (Supplementary Table
S2). Potential synergy, additivity, and antagonism were assessed
based on the Loewe model (Lehar et al., 2007). Full dose response
testing of the individual compounds was also performed in
parallel. The combination of ALDA-112 and ALDA-170 showed a
99.7% (+0.09%) actual percent inhibition compared to the 82.8%
expected percent inhibition if the eﬀect was additive (E. coli;
Supplementary Table S2A) and 42.7% (+0.16%) actual percent
inhibition compared to the 40% expected percent inhibition
(S. Typhimurium; Supplementary Table S2B). Moreover, ALDA-
112 and PRPC-034 showed an actual percent inhibition of
24.8% (+5.17%) compared to the 18.1% expected additive
percent inhibition against S.Typhimurium (Supplementary Table
S2B). Consequently, we subjected ALDA-112, ALDA-170, and
PRPC-034 to a detailed 8x8 combination study to more fully
investigate whether these preliminary 2x2 eﬀects are due to
synergy or addtivity (Figure 4). The anti-microbial activity of the
compounds when used individually was alsomeasured in parallel.
ALDA-112 and ALDA-170 Inhibit the Growth of
E. coli and S. Typhimurium Primarily in an
Additive Manner, but Display Synergy at
100–200 µM Concentration
Against E. coli, ALDA-112 by itself inhibited all bacterial growth
when tested individually at 200 μM (Figure 4A). Because aldA
is not singly essential, this outcome suggested that ALDA-
112 targets a diﬀerent enzyme other than AldA, or it exerts
a non-speciﬁc growth inhibitory eﬀect at this concentration.
ALDA-170 exhibited approximately 60% (58.3 ± 4.6%) growth
inhibition when tested alone at 200 μM, and this eﬀect remained
constant (62.4 ± 0.2%) even when ALDA-112 was present at
concentrations up to 50 μM. However, the addition of 100 μM
ALDA-112 resulted in synergistic inhibition (Figure 4A). Against
S. Typhimurium, ALDA-112 did not inhibit bacterial growth at
200 μM like it did against E. coli (only 8.2% growth inhibition),
but ALDA-170 again displayed nearly constant growth inhibition
when present at this concentration. Together, however, the two
compounds exhibited 79 ± 9.6% growth inhibition when they
were both present at 200 μM (Figure 4A). The two molecules
therefore primarily exhibit an additive eﬀect against the two
bacteria, but exhibit synergistic inhibition at 100–200 μM.
ALDA-112 and PRPC-034 Have No Discernible
Inhibition Pattern against S. Typhimurium
Against E. coli, the combination of ALDA-112 and PRPC-034
likewise exhibited primarily additivity, but displayed one pocket
of synergy and another pocket of antagonism (Figure 4B).
In contrast to ALDA-112 and ALDA-170, antagonism was the
dominant eﬀect when ALDA-112 and PRPC-034 are present
at and above 50–100 μM. Against S. Typhimurium, the two
compounds displayed no discernible pattern because each
compound exhibits low growth inhibition with similar values
at all tested concentrations and often within the expected
experimental uncertainty.
Discussion
Genome-scale metabolic network models can be used
prospectively to guide biological discovery. As new data are
acquired and incorporated, the updated model is used to drive a
new round of biological discovery and reﬁnement. This cyclical
process ultimately yields models that more accurately simulate
experimental outcomes. Here, we traverse one loop of this cycle
by presenting data in which apparent synthetic lethality between
aldA and prpC explains why aldA is not singly essential, which
is the computed phenotype using the most current version
of the E. coli metabolic model (Orth et al., 2011). We also
perform virtual and biological screening against AldA and
PrpC, identifying a pair of compounds that inhibit E. coli and
S. Typhimurium synergistically when the two compounds are
present at 100–200 μM concentration.
Two diﬀerent mechanisms could explain the synthetic
lethality between aldA and prpC. First, the PrpC protein might
directly replace the catalytic function of AldA; however, this
scenario is unlikely as AldA and PrpC have low sequence
and structural overlap (Figure 3). Second, there might be
TABLE 1 | Results of antimicrobial screening against E. coli and S. Typhimurium.
Number of active compounds
Escherichia coli Salmonella Typhimurium
Target protein Number of
compounds tested
IC50 of 0.1–200 µM >30% inhibition at 200 µM IC50 of 0.1–200 µM >30% inhibition at 200 µM
PrpC 99 0 0 0 0
AldA 174 2 2 0 2
The table shows the number of compounds tested for each of the target proteins and their respective activity profile against the two bacteria using repurchased and
reweighed samples.
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FIGURE 4 | Dose response matrix for ALDA-112/ALDA-170, and ALDA-112/PRPC-034 against E. coli and S. Typhimurium. The single agent effects are
depicted in the far left column and along the bottom row of each matrix. Each square represents a unique combination of the indicated compounds, and the number
represents the level of growth inhibition that was measured plus standard deviation. (A) The ALDA-112/ALDA-170 pair exhibits mostly additivite inhibition against
both E. coli and S. Typhimurium, with synergy at 100–200 μM concentration (red boxes). (B) Likewise, ALDA-112/PRPC-034 primarily exhibits additive inhibition at
most concentrations against E. coli but there is one region of synergy (red box) and another region of antagonism (yellow box). No discernible pattern against S.
Typhimurium is observed.
Frontiers in Microbiology | www.frontiersin.org 8 September 2015 | Volume 6 | Article 958
Aziz et al. aldA prpC synthetic lethality
an uncharacterized pathway that consumes glycoaldehyde and
involves PrpC. One possibility is a two step pathway in which
glycolaldehyde is ﬁrst converted to glycolyl-CoA by an unknown
coenzyme A-dependent aldehyde dehydrogenase, followed by
condensation of glycolyl-CoA into products that enter central
metabolism (Supplementary Figure S4). The gene encoding the
enzyme catalyzing the ﬁrst step in this hypothetical pathway
would also be synthetically lethal with aldA, but no such gene was
found in the Tn-mutagenesis screen. This outcome implies that
the transposon did not suﬃciently cover the genome or that more
than one enzyme can catalyze this reaction. For the second step,
citrate synthase (GltA) in other organisms has been shown to be
capable of condensing glycolyl-CoA with oxaloacetate (Vamecq
et al., 1990). Because PrpC has demonstrated citrate synthase
activity (Patton et al., 1993) and they appear to be isozymes
(Guzman et al., 2015), it is possible that PrpC could be required
for the essential condensation of glycolyl-CoA formed in aldA
knockout strains.
The discovery of aldA and prpC as a SL pair arose because the
most current version of the E. coli metabolic model (Orth et al.,
2011) computes aldA as an essential enzyme, but experimentally
it is not. In reality such cases are rare, as metabolic models for
E. coli compute single gene essentiality with accuracy over 90%
(Feist et al., 2007; Orth et al., 2011). The accuracy of prediction
for SL gene pairs is lower, but it is still better than if pairs are
selected by random chance. For S. cerevisiae, for example, the
accuracy is 49% using the S. cerevisiae iLL672 metabolic model,
a rate that is two orders of magnitude better than if two genes
are picked randomly (Harrison et al., 2007). The rate is likely
similar for E. coli. In this context, improving the accuracy with
which metabolic models compute the phenotypic outcome of
gene–gene interactions represents the next stage of reﬁnement
for metabolic models. Similar to single gene experiments, the
workﬂow would likely consist of simulating the phenotype for
large numbers of double deletion mutants and comparing the
results to experimental data. Inconsistencies between the two
then become the foundation for further experimental testing and
model reﬁnement.
Small molecules that inhibit both members of a SL protein pair
are hypothesized to do so synergistically. Synergy among diﬀerent
components in a drug combination is an advantageous property
as it can lead to reduced dosages of the individual compounds
and be more speciﬁc to a particular cellular context (Lehar et al.,
2009). Our screening campaign yielded one pair of compounds
that displayed primarily additive inhibition when present below
100 μM, while synergy appears above this threshold. These
molecules were identiﬁed in a virtual screen against the target
proteins but the biological assay was based on bacterial growth.
Therefore, the observed synergy could be due to other factors.
In addition, factors such as cell permeability and eﬄux could
decrease the synergistic eﬀect. Additional work is warranted
to assess whether the molecules do in fact target AldA and
PrpC in a cellular context. These data point to the diﬃculty
of transferring data from a target-centric screen, implemented
here through virtual screening, to whole-cell assays. Future
studies could be modiﬁed to better account for these factors.
For example, compounds identiﬁed through virtual screening as
PrpC inhibitors could be screened against both the wild-type
bacterium and a aldA mutant. This screen would be repeated
for AldA inhibitors and prpC mutants. Compounds showing
more sensitivity in individual assays toward the two mutants
when compared to the same dosage against the wild-type would
then be tested for synergy.
Conclusion
In this work, we use an inconsistency between simulation and
experimental data to drive new biological insight, ﬁnding that
aldA and prpC form a SL pair, and to investigate whether
this ﬁnding might translate into a biomedical application.
Furthermore, we identify a pair of compounds through virtual
and biological screening that inhibit E. coli and S. Typhimurium
synergistically at 100–200 μM. Follow-up work is needed
to conﬁrm that inhibiton of AldA and PrpC is indeed the
mechanism of action of these molecules, after which structural
reﬁnement based on the core molecular scaﬀolds might lead to
a more potent pair of compounds. More generally, continued
reﬁnement of metabolic models to boost their ability to predict
gene–gene interactions more accurately would improve their
utility across diﬀerent ﬁelds.
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